Followers | 241 |
Posts | 12068 |
Boards Moderated | 0 |
Alias Born | 04/05/2009 |
Monday, December 15, 2014 10:51:55 PM
FORT WORTH — Sundie Ellis, 40, is busy again, working full time for the first time in years.
"Before Lemtrada, I worked about three or four hours a day," she said. "Now I work a full day — plus I help out around the house, which is not something I could do."
Multiple sclerosis triggered serious nerve pain, exhausting fatigue, and mental confusion in Ellis for 11 years. She took 15 medications daily just to function.
In desperation, she traveled to Germany in April to receive infusions of a drug called Lemtrada for five consecutive days. The once-a-year therapy has the potential to help alleviate MS symptoms.
In some cases, lost function has been restored.
Lemtrada was not approved by the Food and Drug Administration for use in the United States when Ellis made her transatlantic journey.
It wasn't the potential for serious side effects — including kidney failure and thyroid cancer — that led to the FDA decision. Rather, Lemtrada had not been tested in double-blind, placebo-controlled studies, like most other drugs.
Lemtrada did have years of testing, however, and had been approved for use in 40 other countries. Many MS patients were willing to travel overseas and pay for the drug out of pocket, at a cost of more than $100,000.
Ellis said not long after the therapy, she stopped needing most of the medications she had been taking.
"And any time you get rid of one medicine, you get rid of the side effects that come with it," she said. "So it was kind of lifting of symptoms, and the day was better."
In November, the FDA approved Lemtrada for use in the U.S.
"Its biggest effect is to give people hope," Ellis said.
Now, she says she has hope and energy to live life again. When she needs another infusion next year, she'll only have to travel down the street — not to Germany — to get it.
http://www.wfaa.com/story/news/health/2014/12/15/lemtrada-approved-for-treatment-of-multiple-sclerosis-in-us/20451859/
[MEI brought this story to my attention]
"Someone said it takes 30 years to be an instant success" - Gabriel Barbier-Mueller, CEO of Harwood International
Recent SNY News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/11/2024 05:54:55 PM
- I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/31/2024 08:30:55 PM
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD • GlobeNewswire Inc. • 05/31/2024 05:05:00 AM
- Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation • GlobeNewswire Inc. • 05/31/2024 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 08:30:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 04:04:28 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/28/2024 02:34:56 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News • IH Market News • 05/21/2024 11:18:35 AM
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) • GlobeNewswire Inc. • 05/13/2024 05:00:00 AM
- Novavax Surges 57% Post $1.4 Billion Sanofi Deal; Apple Boosts Data Centers with AI and Internal Chips, and More News • IH Market News • 05/10/2024 12:02:56 PM
- Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines • PR Newswire (US) • 05/10/2024 06:00:00 AM
- Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings • IH Market News • 04/25/2024 11:52:46 AM
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 02/23/2024 07:02:56 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/23/2024 04:15:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 05:09:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:57:49 PM
- Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) • GlobeNewswire Inc. • 01/25/2024 07:29:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2024 12:23:49 PM
- Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update • Dow Jones News • 01/23/2024 11:05:00 AM
- Wall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and More • IH Market News • 01/23/2024 10:40:18 AM
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B • PR Newswire (US) • 01/23/2024 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 06:49:56 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM